Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States

Abstract

Background-Detailed information on the cost burden of atrial fibrillation (AF) is limited. To provide an up-to-date estimate of the national cost of AF, we conducted a retrospective, observational cohort study using administrative claims from the MarketScan Commercial and Medicare Supplemental research data bases, 2004 to 2006. Methods and Results-Patients aged Ն20 years with Ն1 inpatient or Ն2 outpatient AF diagnoses in 2005 (first diagnosisϭindex) and Ն12 months' enrollment before and after index were selected. AF patients were propensity score-matched (1:1) with non-AF control subjects. Medical costs (2008 US$), including AF costs, other cardiovascular, and noncardiovascular costs, were examined over 1 year after index. National incremental costs of AF were based on age-/sex-specific AF prevalence projections for 2010. In total, 89 066 AF patients were matched to non-AF control subjects. Over 1 year, 37.5% of AF versus 17.5% of control subjects were hospitalized and 2.1% versus 0.1% died during hospitalization. For AF versus control subjects, mean annual inpatient costs per patient were $7841 versus $2622

Impact of Medical Treatment on Long-Term Results after Surgical Ablation of Atrial Fibrillation in Cardiac Surgical Patients

“…20) Despite the better results reported with small atrial size, shorter AF duration, recent joint guidelines on surgical ablation have recommended that all patients undergoing other cardiac surgery should be considered for AF ablation, if the risk of adding the procedure is low and a reasonable chance for success is expected. 7) Meta-analysis from Cheng, et al including 4647 patients showed that, in patients with persistent or permanent AF who present for cardiac surgery, the addition of surgical AF ablation led to a significantly higher rate of SR (~70%) compared with cardiac surgery alone (~20%) at 1 year follow-up. 18) Excellent safety of Epicor HIFU-based System has been amply justified by recent publications.…”

“…4) AF currently represents a major economic burden for society in light of the aging population. [5][6][7] The Maze procedure provides excellent results for surgical treatment of AF. 8) This surgical approach was designed to block multiple macroreentrant circuits that were the putative cause of AF.…”

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…U pacjentów z AF często stwierdza się zmiany w istocie białej mózgu, zaburzenia czynności poznawczych [28][29][30], pogorszenie jakości życia [31,32] oraz obniżony nastrój [33], a każdego roku jest hospitalizowanych 10-40% pacjentów z AF [23,34,35]. Bezpośrednie koszty AF stanowią już w przybliżeniu 1% wszystkich wydatków na opiekę zdrowotną w Wielkiej Brytanii, a w Stanach Zjednoczonych w 2008 roku wyniosły 6-26 mld dolarów [36,37], co wynika z powikłań związanych z AF (np. udar mózgu) oraz kosztów leczenia (np.…”

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation

“…22,23 In summary, annual overall costs for treating AF in the United States are estimated at approximately $6.65 billion, with a national incremental AF cost estimated to range from $6.0 billion to $26.0 billion. [12][13][14] On average, annual excess direct costs of treating AF range from $8,705 to $16,311 per patient (vs. non-AF), with total direct costs ranging from $18,454 to $38,270. Annual inpatient costs range from $7,841 to $22,582 per patient.…”